fr   en
Clinical Studies

Tableaux synoptiques (en anglais)


Parcourir par date
Rechercher par mot clé
Date: 2010-01-06
Phase: II
Anouncement: Launch
Biotech: TopoTarget (Denmark)
Pharma:
Product: Belinostat This histone deacetylase (HDAC) inhibitor is associated with carboplatin.
Disease: platinum-resistant ovarian cancer, fallopian tube, or primary peritoneal cancer
Country: USA
Other: GOG (The Gynecologic Oncology Group, US) has initiated a phase II trial evaluating efficacy and safety of belinostat and carboplatin (BelCar) in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or peritoneal cancer.
GOG receives support for this trial from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).

This study is intended to evaluate the possibility to broaden the group of women with recurrent ovarian cancer who can benefit from re-treatment with carboplatin based therapy by the addition of an epigenetically active agent like belinostat.